Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus

Nature Reviews Endocrinology

Volumn 6, Issue 3, 2010, Pages 131-138

  Petrovsky, Nikolai ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; OM 89; PROBIOTIC AGENT; VSL3;

AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CHILD DEVELOPMENT; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MICROORGANISM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BACTERIAL VACCINES; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOMODULATION; PROBIOTICS; VACCINES; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 77649151308     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.273     Document Type: Review

References (60)

1. Bottazzo, G. F. et al. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N. Engl. J. Med. 313, 353-360 (1985).
2. Foulis, A. K., Liddle, C. N., Farquharson, M. A., Richmond, J. A. &Weir, R. S. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 29, 267-274 (1986).
3. Assan, R. et al. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet 1, 67-71 (1985).
4. De Filippo, G., Carel, J. C., Boitard, C. &Bougnères, P. F. Long-term results of early cyclosporin therapy in juvenile IDDM. Diabetes 45, 101-104 (1996).
5. Stiller, C. R. et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223, 1362-1367 (1984).
6. Rewers, M. &Gottlieb, P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes Care 32, 1769-1782 (2009).
7. Bresson, D. &von Herrath, M. Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside. Diabetes Care 32, 1753-1768 (2009).
8. Petrovsky, N., Silva, D. &Schatz, D. A. Prospects for the prevention and reversal of type 1 diabetes mellitus. Drugs 62, 2617-2635 (2002).
9. Petrovsky, N., Silva, D. &Schatz, D. A. Vaccine therapies for the prevention of type 1 diabetes mellitus. Paediatr. Drugs 5, 575-582 (2003).
10. Makino, S. et al. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29, 1-13 (1980).
11. Crisá, L., Mordes, J. P. &Rossini, A. A. Autoimmune diabetes mellitus in the BB rat. Diabetes Metab. Rev. 8, 4-37 (1992).
12. Kühtreiber, W. M., Hayashi, T., Dale, E. A. &Faustman, D. L. Central role of defective apoptosis in autoimmunity. J. Mol. Endocrinol. 31, 373-399 (2003).
13. Bach, J. F. Infections and autoimmune diseases. J. Autoimmun. 25 (Suppl.), 74-80 (2005).
14. Kukreja, A. &Maclaren, N. K. NKT cells and type-1 diabetes and the "hygiene hypothesis" to explain the rising incidence rates. Diabetes Technol. Ther. 4, 323-333 (2002).
15. Mazmanian, S. K., Liu, C. H., Tzianabos, A. O. &Kasper, D. L. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122, 107-118 (2005).
16. Hansen, A. K. et al. Diabetes preventive glutenfree diet decreases the number of caecal bacteria in non-obese diabetic mice. Diabetes Metab. Res. Rev. 22, 220-225 (2006).
17. Sadelain, M. W., Qin, H. Y., Lauzon, J. &Singh, B. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 39, 583-589 (1990).
18. Sadelain, M. W. et al. Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant. J. Autoimmun. 3, 671-680 (1990).
19. Harada, M., Kishimoto, Y. &Makino, S. Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diabetes Res. Clin. Pract. 8, 85-89 (1990).
20. Shehadeh, N. et al. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 343, 706-707 (1994).
21. Elliott, J. F., Marlin, K. L. &Couch, R. M. Effect of bacille Calmette-Guérin vaccination on C-peptide secretion in children newly diagnosed with IDDM. Diabetes Care 21, 1691-1693 (1998).
22. Gazda, L. S., Baxter, A. G. &Lafferty, K. J. Regulation of autoimmune diabetes: characteristics of non-islet-antigen specific therapies. Immunol. Cell Biol. 74, 401-407 (1996).
23. Zaccone, P., Fehervari, Z., Phillips, J. M., Dunne, D. W. &Cooke, A. Parasitic worms and inflammatory diseases. Parasite Immunol. 28, 515-523 (2006).
24. Cooke, A. et al. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice. Parasite Immunol. 21, 169-176 (1999).
25. Saunders, K. A., Raine, T., Cooke, A. &Lawrence, C. E. Inhibition of autoimmune type 1 diabetes by gastrointestinal helminth infection. Infect. Immun. 75, 397-407 (2007).
26. Oldstone, M. B. Prevention of type I diabetes in nonobese diabetic mice by virus infection. Science 239, 500-502 (1988).
27. Oldstone, M. B. Viruses as therapeutic agents. I. Treatment of nonobese insulin-dependent diabetes mice with virus prevents insulindependent diabetes mellitus while maintaining general immune competence. J. Exp. Med. 171, 2077-2089 (1990).
28. Like, A. A., Guberski, D. L. &Butler, L. Influence of environmental viral agents on frequency and tempo of diabetes mellitus in BB/Wor rats. Diabetes 40, 259-262 (1991).
29. Heggers, J. P., Mallavia, L. P. &Hinrichs, D. J. The cellular immune response to antigens of Coxiella burneti. Can. J. Microbiol. 20, 657-662 (1974).
30. Izzo, A. A. &Marmion, B. P. Variation in interferongamma responses to Coxiella burnetii antigens with lymphocytes from vaccinated or naturally infected subjects. Clin. Exp. Immunol. 94, 507-515 (1993).
31. Jerrells, T. R., Mallavia, L. P. &Hinrichs, D. J. Detection of long-term cellular immunity to Coxiella burneti as assayed by lymphocyte transformation. Infect. Immun. 11, 280-286 (1975).
32. Aitken, I. D. et al. Q fever in Europe: current aspects of aetiology, epidemiology, human infection, diagnosis and therapy. Infection 15, 323-327 (1987).
33. Sawyer, L. A., Fishbein, D. B. &McDade, J. E. Q fever: current concepts. Rev. Infect. Dis. 9, 935-946 (1987).
34. Clark, I. A. Resistance to Babesia spp. and Plasmodium sp. in mice pretreated with an extract of Coxiella burnetii. Infect. Immun. 24, 319-325 (1979).
35. Waag, D. M., Kende, M., Damrow, T. A., Wood, O. L. &Williams, J. C. Injection of inactivated phase I Coxiella burnetii increases nonspecific resistance to infection and stimulates lymphokine production in mice. Ann. NY Acad. Sci. 590, 203-214 (1990).
36. Silva, D. G., Charlton, B., Cowden, W. &Petrovsky, N. Prevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen. Ann. NY Acad. Sci. 1005, 423-430 (2003).
37. Cowden, W. B., Cullen, F. A., Staykova, M. A. &Willenborg, D. O. Nitric oxide is a potential downregulating molecule in autoimmune disease: inhibition of nitric oxide production renders PVG rats highly susceptible to EAE. J. Neuroimmunol. 88, 1-8 (1998).
38. Kelly, C. J. &Gold, D. P. Nitric oxide in interstitial nephritis and other autoimmune diseases. Semin. Nephrol. 19, 288-295 (1999).
39. Staykova, M. A., Cowden, W. &Willenborg, D. O. Macrophages and nitric oxide as the possible cellular and molecular basis for strain and gender differences in susceptibility to autoimmune central nervous system inflammation. Immunol. Cell Biol. 80, 188-197 (2002).
40. Saï, P. &Rivereau, A. S. Prevention of diabetes in the nonobese diabetic mouse by oral immunological treatments. Comparative efficiency of human insulin and two bacterial antigens, lipopolysacharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae. Diabetes Metab. 22, 341-348 (1996).
41. Hartmann, B., Bellmann, K., Ghiea, I., Kleemann, R. &Kolb, H. Oral insulin for diabetes prevention in NOD mice: potentiation by enhancing Th2 cytokine expression in the gut through bacterial adjuvant. Diabetologia 40, 902-909 (1997).
42. Quintana, F. J., Rotem, A., Carmi, P. &Cohen, I. R. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J. Immunol. 165, 6148-6155 (2000).
43. Lee, B. J. et al. Limited effect of CpG ODN in preventing type 1 diabetes in NOD mice. Yonsei Med. J. 46, 341-346 (2005).
44. Alyanakian, M. A. et al. Transforming growth factor-beta and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes. Diabetes 55, 179-185 (2006).
45. Ola, T. O. &Williams, N. A. Protection of nonobese diabetic mice from autoimmune diabetes by Escherichia coli heat-labile enterotoxin B subunit. Immunology 117, 262-270 (2006).
46. Lewis, D. J. et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4, e6999 (2009).
47. Calcinaro, F. et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the nonobese diabetic mouse. Diabetologia 48, 1565-1575 (2005).
48. Miele, E. et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol. 104, 437-443 (2009).
49. Matsuzaki, T. et al. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. APMIS 105, 643-649 (1997).
50. Matsuzaki, T., Yamazaki, R., Hashimoto, S. &Yokokura, T. Antidiabetic effects of an oral administration of Lactobacillus casei in a non-insulin-dependent diabetes mellitus (NIDDM) model using KK-Ay mice. Endocr. J. 44, 357-365 (1997).
51. Matsuzaki, T. et al. Effect of oral administration of Lactobacillus casei on alloxan-induced diabetes in mice. APMIS 105, 637-642 (1997).
52. Ljungberg, M., Korpela, R., Ilonen, J., Ludvigsson, J. &Vaarala, O. Probiotics for the prevention of beta cell autoimmunity in children at genetic risk of type 1 diabetes--the PRODIA study. Ann. NY Acad. Sci. 1079, 360-364 (2006).
53. Luross, J. A., Heaton, T., Hirst, T. R., Day, M. J. &Williams, N. A. Escherichia coli heat-labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells. Arthritis Rheum. 46, 1671-1682 (2002).
54. Sewell, D. L. et al. Infection with Mycobacterium bovis BCG diverts traffic of myelin oligodendroglial glycoprotein autoantigenspecific T cells away from the central nervous system and ameliorates experimental autoimmune encephalomyelitis. Clin. Diagn. Lab. Immunol. 10, 564-572 (2003).
55. Qu, P., Ji, R. C., Shimoda, H., Miura, M. &Kato, S. Study on pancreatic lymphatics in nonobese diabetic mouse with prevention of insulitis and diabetes by adjuvant immunotherapy. Anat. Rec. A Discov. Mol. Cell Evol. Biol. 281, 1326-1336 (2004).
56. Raine, T., Zaccone, P., Mastroeni, P. &Cooke, A. Salmonella typhimurium infection in nonobese diabetic mice generates immunomodulatory dendritic cells able to prevent type 1 diabetes. J. Immunol. 177, 2224-2233 (2006).
57. Zaccone, P. et al. Salmonella typhimurium infection halts development of type 1 diabetes in NOD mice. Eur. J. Immunol. 34, 3246-3256 (2004).
58. Wen, L. et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 455, 1109-1113 (2008).
59. Funda, D. P., Kaas, A., Tlaskalová-Hogenová, H. &Buschard, K. Gluten-free but also glutenenriched (gluten+) diet prevent diabetes in NOD mice; the gluten enigma in type 1 diabetes. Diabetes Metab. Res. Rev. 24, 59-63 (2008).
60. Maslowski, K. M. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282-1286 (2009).